Drugs / HuHuangLianzonggan capsule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05632861 | Feb 2023 → Dec 2024 overdue | metabolic dysfunction-associated steatohepatitis | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HuHuangLianzonggan capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05632861 ↗ |
| Route | Oral | “take orally after meals” NCT05632861 ↗ |